Crinetics Pharmaceuticals Presents at ENDO 2025 Meeting

The latest announcement is out from Crinetics Pharmaceuticals ( (CRNX) ).

On June 30, 2025, Crinetics Pharmaceuticals announced that it will present eight abstracts from its clinical development programs at the Endocrine Society’s Annual Meeting, ENDO 2025, in San Francisco. The presentations will include long-term efficacy and safety data on PALSONIFY for acromegaly, results from a Phase 2 trial of atumelnant for congenital adrenal hyperplasia, and early-stage data on CRN12755 for Graves’ hyperthyroidism. These developments highlight Crinetics’ commitment to addressing unmet needs in endocrine disorders and reinforce its position as a leader in endocrine-focused pharmaceutical innovation.

The most recent analyst rating on (CRNX) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Crinetics Pharmaceuticals stock, see the CRNX Stock Forecast page.

Spark’s Take on CRNX Stock

According to Spark, TipRanks’ AI Analyst, CRNX is a Neutral.

Crinetics Pharmaceuticals’ overall stock score reflects substantial financial challenges and negative valuation aspects, partially offset by a positive earnings call and promising corporate events. The financial performance and technical analysis weigh heavily on the score, with recent strategic advancements providing a more optimistic long-term outlook.

To see Spark’s full report on CRNX stock, click here.

More about Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a global pharmaceutical company focused on developing innovative endocrine therapies. The company specializes in creating oral treatments for endocrine disorders, with a market focus on conditions such as acromegaly, congenital adrenal hyperplasia, and carcinoid syndrome.

Average Trading Volume: 905,327

Technical Sentiment Signal: Sell

Current Market Cap: $2.81B

See more data about CRNX stock on TipRanks’ Stock Analysis page.